Gap19Cx43 hemichannel blocker CAS# 1507930-57-5 |
- Scrambled 10Panx
Catalog No.:BCC1246
CAS No.:1315378-72-3
- Gap 26
Catalog No.:BCC1032
CAS No.:197250-15-0
- 10Panx
Catalog No.:BCC1245
CAS No.:955091-53-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1507930-57-5 | SDF | Download SDF |
PubChem ID | 91691126 | Appearance | Powder |
Formula | C55H96N14O13 | M.Wt | 1161.45 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 2 mg/ml in water | ||
Sequence | KQIEIKKFK | ||
Chemical Name | (2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-2,6-diaminohexanoyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]hexanoic acid | ||
SMILES | CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CCCCN)C(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)N | ||
Standard InChIKey | IEAKEKFIXUZWEH-PKMKMBMKSA-N | ||
Standard InChI | InChI=1S/C55H96N14O13/c1-5-33(3)45(69-51(77)40(25-27-44(71)72)65-54(80)46(34(4)6-2)68-50(76)39(24-26-43(61)70)62-47(73)36(60)20-10-14-28-56)53(79)64-38(22-12-16-30-58)48(74)63-37(21-11-15-29-57)49(75)67-42(32-35-18-8-7-9-19-35)52(78)66-41(55(81)82)23-13-17-31-59/h7-9,18-19,33-34,36-42,45-46H,5-6,10-17,20-32,56-60H2,1-4H3,(H2,61,70)(H,62,73)(H,63,74)(H,64,79)(H,65,80)(H,66,78)(H,67,75)(H,68,76)(H,69,77)(H,71,72)(H,81,82)/t33-,34-,36-,37-,38-,39-,40-,41-,42-,45-,46-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective connexin 43 (Cx43) hemichannel blocker; has no effect on gap junction coupling or Panx-1 channels. Reduces mitochondrial potassium influx in cardiomyocytes and attenuates glutamate-triggered ATP release in primary astrocytes. Modestly reduces infarct size in a mouse ischemia model. |
Gap19 Dilution Calculator
Gap19 Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Drynachromoside A
Catalog No.:BCN7891
CAS No.:1507388-29-5
- Calyxamine B
Catalog No.:BCN1671
CAS No.:150710-72-8
- 5-Methoxycanthin-6-one
Catalog No.:BCN3326
CAS No.:15071-56-4
- Tolvaptan
Catalog No.:BCC5096
CAS No.:150683-30-0
- Fmoc-Lys(Dde)-OH
Catalog No.:BCC3518
CAS No.:150629-67-7
- epi-Eudesmol
Catalog No.:BCN1670
CAS No.:15051-81-7
- L-NIL hydrochloride
Catalog No.:BCC5706
CAS No.:150403-89-7
- o-Methoxycinnamaldehyde
Catalog No.:BCN3860
CAS No.:1504-74-1
- Pemetrexed disodium
Catalog No.:BCN2179
CAS No.:150399-23-8
- MRS 2690
Catalog No.:BCC7514
CAS No.:15039-58-4
- SR 49059
Catalog No.:BCC7324
CAS No.:150375-75-0
- Sivelestat sodium salt
Catalog No.:BCC2368
CAS No.:150374-95-1
- Oxybutynin chloride
Catalog No.:BCC4149
CAS No.:1508-65-2
- Tropicamide
Catalog No.:BCC4574
CAS No.:1508-75-4
- Retigabine
Catalog No.:BCC6427
CAS No.:150812-12-7
- Retigabine dihydrochloride
Catalog No.:BCC1890
CAS No.:150812-13-8
- 2,3,24-Trihydroxyolean-12-en-28-oic acid
Catalog No.:BCN1559
CAS No.:150821-16-2
- Nitenpyram
Catalog No.:BCC5559
CAS No.:150824-47-8
- EGF816
Catalog No.:BCC6428
CAS No.:1508250-71-2
- Boc-Orn(Fmoc)-OH
Catalog No.:BCC3429
CAS No.:150828-96-9
- Micromelin
Catalog No.:BCN1672
CAS No.:15085-71-9
- Uralenol-3-methylether
Catalog No.:BCN7993
CAS No.:150853-98-8
- Bis(phenylacetyl) disulfide
Catalog No.:BCC8887
CAS No.:15088-78-5
- Euonymine
Catalog No.:BCN3084
CAS No.:150881-01-9
The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes.[Pubmed:25374505]
Front Cell Neurosci. 2014 Oct 21;8:306.
In the brain, astrocytes represent the cellular population that expresses the highest amount of connexins (Cxs). This family of membrane proteins is the molecular constituent of gap junction channels and hemichannels that provide pathways for direct cytoplasm-to-cytoplasm and inside-out exchange, respectively. Both types of Cx channels are permeable to ions and small signaling molecules allowing astrocytes to establish dynamic interactions with neurons. So far, most pharmacological approaches currently available do not distinguish between these two channel functions, stressing the need to develop new specific molecular tools. In astrocytes two major Cxs are expressed, Cx43 and Cx30, and there is now evidence indicating that at least Cx43 operates as a gap junction channel as well as a hemichannel in these cells. Based on studies in primary cultures as well as in acute hippocampal slices, we report here that Gap19, a nonapeptide derived from the cytoplasmic loop of Cx43, inhibits astroglial Cx43 hemichannels in a dose-dependent manner, without affecting gap junction channels. This peptide, which not only selectively inhibits hemichannels but is also specific for Cx43, can be delivered in vivo in mice as TAT-Gap19, and displays penetration into the brain parenchyma. As a result, Gap19 combined with other tools opens up new avenues to decipher the role of Cx43 hemichannels in interactions between astrocytes and neurons in physiological as well as pathological situations.
Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury.[Pubmed:23184389]
Basic Res Cardiol. 2013 Jan;108(1):309.
Connexin-43 (Cx43), a predominant cardiac connexin, forms gap junctions (GJs) that facilitate electrical cell-cell coupling and unapposed/nonjunctional hemichannels that provide a pathway for the exchange of ions and metabolites between cytoplasm and extracellular milieu. Uncontrolled opening of hemichannels in the plasma membrane may be deleterious for the myocardium and blocking hemichannels may confer cardioprotection by preventing ionic imbalance, cell swelling and loss of critical metabolites. Currently, all known hemichannel inhibitors also block GJ channels, thereby disturbing electrical cell-cell communication. Here we aimed to characterize a nonapeptide, called Gap19, derived from the cytoplasmic loop (CL) of Cx43 as a hemichannel blocker and examined its effect on hemichannel currents in cardiomyocytes and its influence in cardiac outcome after ischemia/reperfusion. We report that Gap 19 inhibits Cx43 hemichannels without blocking GJ channels or Cx40/pannexin-1 hemichannels. Hemichannel inhibition is due to the binding of Gap19 to the C-terminus (CT) thereby preventing intramolecular CT-CL interactions. The peptide inhibited Cx43 hemichannel unitary currents in both HeLa cells exogenously expressing Cx43 and acutely isolated pig ventricular cardiomyocytes. Treatment with Gap19 prevented metabolic inhibition-enhanced hemichannel openings, protected cardiomyocytes against volume overload and cell death following ischemia/reperfusion in vitro and modestly decreased the infarct size after myocardial ischemia/reperfusion in mice in vivo. We conclude that preventing Cx43 hemichannel opening with Gap19 confers limited protective effects against myocardial ischemia/reperfusion injury.
Connexin 43 impacts on mitochondrial potassium uptake.[Pubmed:23760924]
Front Pharmacol. 2013 Jun 6;4:73.
In cardiomyocytes, connexin 43 (Cx43) forms gap junctions and unopposed hemichannels at the plasma membrane, but the protein is also present at the inner membrane of subsarcolemmal mitochondria (SSM). Both inhibition and genetic ablation of Cx43 reduce ADP-stimulated complex 1 respiration. Since mitochondrial potassium influx impacts on oxygen consumption, we investigated whether or not inhibition or ablation of mitochondrial Cx43 alters mitochondrial potassium uptake. SSM were isolated from rat left ventricular myocardium and loaded with the potassium-sensitive dye PBFI (potassium-binding benzofuran isophthalate). Intramitochondrial potassium was replaced by tetraethylammonium. Mitochondria were incubated under control conditions or treated with 250 muM Gap19, a peptide that specifically inhibits Cx43-based hemichannels at plasma membranes. Subsequently, 140 mM KCl was added and the slope of the increase in PBFI fluorescence over time was calculated. The slope of the PBFI fluorescence of the control mitochondria was set to 100%. In the presence of Gap19, the mitochondrial potassium influx was reduced from 100 +/- 11.6% in control mitochondria to 65.5 +/- 10.7% (n = 6, p < 0.05). In addition to the pharmacological inhibition of Cx43, potassium influx was studied in mitochondria isolated from conditional Cx43 knockout mice. Here, the ablation of Cx43 was achieved by the injection of 4-hydroxytamoxifen (4-OHT; Cx43(Cre-ER(T)/fl) + 4-OHT). The mitochondria of the Cx43(Cre-ER(T)/fl) + 4-OHT mice contained 3 +/- 1% Cx43 (n = 6) of that in control mitochondria (100 +/- 11%, n = 8, p < 0.05). The ablation of Cx43 (n = 5) reduced the velocity of the potassium influx from 100 +/- 11.2% in control mitochondria (n = 9) to 66.6 +/- 5.5% (p < 0.05). Taken together, our data indicate that both pharmacological inhibition and genetic ablation of Cx43 reduce mitochondrial potassium influx.